Skip to main content
Clinical Trials/IRCT201607254920N8
IRCT201607254920N8
Completed
Phase 3

Double-blinde, randomized clinical trial on efficacy and safety of Dixopaque (Shahid Ghazi) contrast media and Visipaque in coronary angiography

Shahid Ghazi Pharmaceutical Company0 sites50 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Patients candidated for coronary angiography by contrast media.
Sponsor
Shahid Ghazi Pharmaceutical Company
Enrollment
50
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Shahid Ghazi Pharmaceutical Company

Eligibility Criteria

Inclusion Criteria

  • patients aged between 45 to 65 years old; referred subjects for coronary angiography by contrast media; provided signed and dated informed consent subjects. Exclusion criteria: patients with contrast administration in the past 7 days; subjects have known contra\-indication and allergy to contrast administration; renal insufficiency as defined by GFR \< 50; lactation; pregnancy; bronchial asthma; clinical unstable condition (hemodynamic, respiratory, neurologic); emergency cases; hyperthyroidism; end\-stage patients.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials